Nimodipine in subarachnoid hemorrhage

Area of Science:

• Pharmacology
• Neurology
• Critical Care Medicine

Background:

• Subarachnoid hemorrhage frequently leads to cerebral ischemia and vasospasm.
• Nimodipine, a dihydropyridine calcium channel blocker, exhibits high lipid solubility and selectivity for cerebral vasculature.
• Previous studies indicated nimodipine reduces morbidity and mortality associated with post-subarachnoid hemorrhage cerebral ischemia.

Purpose of the Study:

• To evaluate the efficacy and safety of nimodipine in treating cerebral ischemia following subarachnoid hemorrhage.
• To review the current evidence regarding nimodipine's benefits and limitations in clinical practice.

Main Methods:

• Review of clinical studies and recent trial data on nimodipine.
• Analysis of nimodipine's pharmacological properties, including lipid solubility and cerebral selectivity.
• Assessment of reported patient outcomes, including morbidity and mortality rates.

Main Results:

• Nimodipine is approved for cerebral ischemia post-subarachnoid hemorrhage.
• While generally well-tolerated with low toxicity at recommended doses, recent studies have raised questions about its consistent benefit.
• The drug demonstrates greater lipid solubility and cerebral blood vessel selectivity compared to similar calcium channel blockers.

Conclusions:

• Nimodipine's role in reducing morbidity and mortality from cerebral ischemia after subarachnoid hemorrhage is under ongoing evaluation.
• Despite potential benefits, alternative or adjunctive treatments for vasospasm should not be overlooked when using nimodipine.
• Further research is warranted to clarify the definitive clinical utility of nimodipine in this indication.